Aidoc vs Lunit
The enterprise acute platform against the cancer screening specialist. Aidoc runs detection across an imaging estate through an operating system handling normalisation, monitoring and governance, with a 2026 clearance covering many acute indications from one named foundation model. Lunit works cancer detection on chest radiographs and mammograms, with the deeper evidence base in screening populations and a listed parent behind it. They answer different questions on different clocks: acute triage is judged on time to treatment, screening on positive predictive value at your prevalence. A health system may run both in different departments, and the mistake to avoid is comparing them on sensitivity, which tells you nothing about either job.
- It runs many detection models across an imaging estate through an operating system handling normalisation, monitoring and governance for every model on it.
- The 2026 clearance covers a double digit set of acute indications from a single named foundation model, with regulator reviewed performance behind it.
- For a health system, the platform outlives whichever individual algorithms get replaced.
- Cancer detection across chest radiograph and mammography is the portfolio, with a listed parent and regulatory footprints in multiple markets.
- The evidence base in screening populations is deeper than most detection vendors, which is where specificity multiplies across a large healthy denominator.
- For a screening programme, a vendor built around cancer detection is the closer fit than an acute triage platform.
Side by Side
| Axis | A Aidoc |
L Lunit |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
These operate on different clocks and their evidence is not interchangeable: an acute platform is judged on time to treatment while a screening product is judged on positive predictive value at your prevalence, and comparing them on sensitivity settles nothing. Neither publishes subgroup performance. Findings counts and indication counts are not comparable between vendors because each defines them differently, so ask both for performance on the findings your population actually presents with.